Therapeutic antibodies and other proteins obtained by molecular display technologies

Recent Patents on Biotechnology

Volumn 3, Issue 1, 2009, Pages 19-27

  Shibasaki, Seiji ^a   Ueda, Mitsuyoshi ^b  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Affibody; Fc domain; Molecular display; Monoclonal antibody; Phage; Ribosome; Romiplostim; Therapeutic antibody; TPO; Yeast

Indexed keywords

BUDGET CONTROL; CELLS; CYTOLOGY; GENETIC ENGINEERING;

AFFIBODY; DISPLAY TECHNOLOGIES; FC DOMAIN; MOLECULAR DISPLAY; PHARMACEUTICAL COMPANY; RIBOSOME; ROMIPLOSTIM; THERAPEUTIC AGENTS; THERAPEUTIC ANTIBODIES; TPO;

MONOCLONAL ANTIBODIES;

ABCIXIMAB; ADALIMUMAB; AGGLUTININ; ALEMTUZUMAB; ATLIZUMAB; BASILIXIMAB; BEVACIZUMAB; CELL MEMBRANE PROTEIN; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; GLYCOSYLPHOSPHATIDYLINOSITOL; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G; INFLIXIMAB; NATALIZUMAB; OKT 3; OMALIZUMAB; ORTHOCLONE; PALIVIZUMAB; PANITUMUMAB; PLACEBO; RANIBIZUMAB; RECOMBINANT THROMBOPOIETIN; RITUXIMAB; ROMIPLOSTIM; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; MONOCLONAL ANTIBODY; PEPTIDE LIBRARY;

ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN BINDING; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESEARCH; DRUG SCREENING; FUNGAL CELL; GENETIC ENGINEERING; GRAM POSITIVE BACTERIUM; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PATENT; PHAGE DISPLAY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SACCHAROMYCES CEREVISIAE; BIOTECHNOLOGY; GENETIC PROCEDURES; PROTEIN ENGINEERING;

ANTIBODIES, MONOCLONAL; BIOTECHNOLOGY; MOLECULAR PROBE TECHNIQUES; PATENTS AS TOPIC; PEPTIDE LIBRARY; PROTEIN ENGINEERING;

EID: 62149115313     PISSN: 18722083     EISSN: None     Source Type: Journal    
DOI: 10.2174/187220809787172641     Document Type: Review

References (98)

1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
2. Sinnott JT 4th, Cullison JP, Sweeney MS, Weinstein SS. Infections in patients receiving OKT3 monoclonal antibody for cardiac rejection: Results of a small clinical trial. Tex Heart Inst J 1988; 15: 102-106.
3. Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC Jr. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985; 45: 879-885.
4. Shawler DL, Bartholomew RM, Smith LM, Dillman RO. Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985; 135: 1530-1535.
5. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984; 81: 6851-6855.
6. Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature 1984; 312: 643-646.
7. Verhoeyen M, Milstein C, Winter G. Reshaping human antibodies: grafting an antilysozyme activity. Science 1988; 239: 1534-1536.
8. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323-327.
9. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
10. Ng M, Cunningham D. Cetuximab (Erbitux)-an emerging targeted therapy for epidermal growth factor receptor-expressing tumours. Int J Clin Pract 2004; 58: 970-976.
11. Smith GP. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228: 1315-1317.
12. Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science 1990; 249: 386-390.
13. Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P, Winter G. Multi-subunit proteins on the surface of filamentous phage: Methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res 1991; 19: 4133-4137.
14. Fujii I, Fukuyama S, Iwabuchi Y, Tanimura R. Evolving catalytic antibodies in a phage-displayed combinatorial library. Nat Biotechnol 1998; 16: 463-467.
15. Smith GP, Petrenko VA. Phage display. Chem Rev 1997; 97: 391-410.
16. Jespers LS, Messens JH, De Keyser A, et al. Surface expression and ligand-based selection of cDNAs fused to filamentous phage gene VI. Biotechnology (NY) 1995; 13: 378-382.
17. Hoess RH. Protein design and phage display. Chem Rev 2001; 101: 3205-3218.
18. Gao C, Mao S, Lo CH, Wirsching P, Lerner RA, Janda KD. Making artificial antibodies: A format for phage display of combinatorial heterodimeric arrays. Proc Natl Acad Sci USA 1999; 96: 6025-6030.
19. Widersten M, Mannervik B. Glutathione transferases with novel active sites isolated by phage display from a library of random mutants. J Mol Biol 1995; 250: 115-122.
20. Hansson LO, Widersten M, Mannervik B. Mechanism-based phage display selection of active-site mutants of human glutathione transferase A1-1 catalyzing SNAr reactions. Biochemistry 1997; 36: 11252-11260.
21. Ley, A.C., Luneau, C.J., Ladner, R.C.: US20056906176 (2005).
22. Soumillion P, Jespers L, Bouchet M, Marchand-Brynaert J, Winter G, Fastrez J. Selection of beta-lactamase on filamentous bacteriophage by catalytic activity. J Mol Biol 1994; 237: 415-422.
23. Baca M, Scanlan TS, Stephenson RC, Wells JA. Phage display of a catalytic antibody to optimize affinity for transition-state analog binding. Proc Natl Acad Sci USA 1997; 94: 10063-10068.
24. Ladner, R.C., Guterman, S.K., Roberts, B.L., Markland, W., Ley, A.C., Kent, RB.: US5223409 (1993).
25. Schatz, P.J., Cull, M.G., Miller, J.F., Stemmer, W.P.C., Gates, C.M.: US5733731 (1998).
26. Markvardsen, P., Bjornvad, M.E., Mikkelsen, F., Diderichsen, B.: US20016194183 (2001).
27. Nolan, G.P., Rozinov, M.N.: US20087332356 (2008).
28. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol 1994; 12: 433-455.
29. Webster R. Filamentous phage biology. In: Barbas CF, Burton DR, Scott JK, Silverman, Eds. Phage Display: A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor 2001.
30. Watkins, B.A., Reitz, M.S.J.: WO01000678 (2001).
31. Furuichi, Y., Komiyama, T.: WO2006093071 (2006).
32. Andersen, P.S., Buus, S., Engberg, J., Fugger, L., Stryhn, A.: WO97002342 (1997).
33. Francisco JA, Stathopoulos C, Warren RA, Kilburn DG, Georgiou G. Specific adhesion and hydrolysis of cellulose by intact Escherichia coli expressing surface anchored cellulase or cellulose binding domains. Biotechnology (NY) 1993; 11: 491-495.
34. Wentzel A, Christmann A, Adams T, Kolmar H. Display of passenger proteins on the surface of Escherichia coli K-12 by the enterohemorrhagic E. coli intimin EaeA. J Bacteriol 2001; 183: 7273-7284.
35. Hedegaard L, Klemm P. Type 1 fimbriae of Escherichia coli as carriers of heterologous antigenic sequences. Gene 1989; 85: 115-124.
36. Westerlund-Wikström B. Peptide display on bacterial flagella: Principles and applications. Int J Med Microbiol 2000; 290: 223-230.
37. Samuelson P, Cano F, Robert A, Sth̊l S. Engineering of a Staphylococcus carnosus surface display system by substitution or deletion of a Staphylococcus hyicus lipase propeptide. FEMS Microbiol Lett 1999; 179: 131-139.
38. Narita J, Okano K, Kitao T, et al. Display of alpha-amylase on the surface of Lactobacillus casei cells by use of the PgsA anchor protein, and production of lactic acid from starch. Appl Environ Microbiol 2006; 72: 269-275.
39. Piard JC, Hautefort I, Fischetti VA, Ehrlich SD, Fons M, Gruss A. Cell wall anchoring of the Streptococcus pyogenes M6 protein in various lactic acid bacteria. J Bacteriol 1997; 179: 3068-3072.
40. Bernasconi E, Germond JE, Delley M, Fritsché R, Corthésy B. Lactobacillus bulgaricus proteinase expressed in Lactococcu lactis is a powerful carrier for cell wall-associated and secreted bovine beta-lactoglobulin fusion proteins. Appl Environ Microbiol 2002; 68: 2917-2923.
41. Ueda M, Tanaka A. Genetic immobilization of proteins on the yeast cell surface. Biotechnol Adv 2000; 18: 121-140.
42. Ueda M, Tanaka A. Cell surface engineering of yeast: Construction of arming yeast with biocatalyst. J Biosci Bioeng 2000; 90: 125-136.
43. Kondo A, Ueda M. Yeast cell-surface display-applications of molecular display. Appl Microbiol Biotechnol 2004; 64: 28-40.
44. Fukuda, H., Kondo, A., Tanaka, A., Ueda, M., Satoh, E.: WO03016525 ( 2003).
45. Kondo, A., Kuroda, S., Ueda, M., Fukuda, H., Tatematsu, K., Yamazaki, T.: WO2006104254 (2006).
46. Anonymous. Arming yeast with cell-surface catalysts. Chem Eng News 1997; 75: 32.
47. Shibasaki S, Maeda H, Ueda M. Molecular display technology using yeast - Arming technology. Anal Sci 2009; 1: (in press).
48. Mattheakis LC, Bhatt RR, Dower WJ. An in vitro polysome display system for identifying ligands from very large peptide libraries. Proc Natl Acad Sci USA 1994; 91: 9022-9026.
49. Hanes J, Plückthun A. In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci USA 1997; 94: 4937-4942.
50. Kawasaki, G.H.: US5643768 (1997).
51. Osbourn, J., Holet, T.: US20067074557 (2006).
52. Buchanan, A., Jermutus, L., Walton, S.: WO2006072773 (2006).
53. Kuter DJ. New drugs for familiar therapeutic targets: Thrombopoietin receptor agonists and immune thrombocytopenic purpura. Eur J Haematol Suppl 2008; 69: 9-18.
54. Frederickson S, Renshaw MW, Lin B, et al. A rationally designed agonist antibody fragment that functionally mimics thrombopoietin. Proc Natl Acad Sci USA 2006; 103:14307-14312.
55. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100: 3457-3469.
56. Schwertschlag U, Turner KJ, Schendel P. in Platelets. Michelson AD, Ed. Academic, San Diego, USA 2002; 845-854.
57. Harker LA, Roskos LK, Marzec UM, et al. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 2000; 95: 2514-2522.
58. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997; 126: 673-681.
59. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatininduced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000; 132: 364-368.
60. Bartley, T.D., Bogenberger, J.M., Bosselman, R.A., Hunt, P., Kinstler, O.B., Samal, B.B.: WO95026746 (1995).
61. Cwirla SE, Balasubramanian P, Duffin DJ, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997; 276: 1696-1699.
62. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371: 395-403
63. Feige, U.: US20077189827 (2007).
64. Nygren PA. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 2008; 275: 2668-2676.
65. Binz HK, Amstutz P, Plückthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 2005; 23: 1257-1268.
66. Stumpp, M.T., Forrer, P., Binz, H.K., Pluckthun, A.: US20087417130 ( 2008).
67. Nilsson, B., Nygren, P.A. Uhlen, M.: WO95019374 (1995).
68. Ljungqvist, C., Nord, K., Nygren, P.A., Uhlen, M.: WO00063243 (2000).
69. Nord K, Nilsson J, Nilsson B, Uhlén M, Nygren PA. A combinatorial library of an alpha-helical bacterial receptor domain. Protein Eng 1995; 8: 601-608.
70. Nord K, Gunneriusson E, Ringdahl J, Ståhl S, Uhlén M, Nygren PA. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 1997; 15: 772-777.
71. Nord K, Gunneriusson E, Uhlén M, Nygren PA. Ligands selected from combinatorial libraries of protein A for use in affinity capture of apolipoprotein A-1M and taq DNA polymerase. J Biotechnol 2000; 80(1): 45-54.
72. Nord K, Nord O, Uhlén M, Kelley B, Ljungqvist C, Nygren PA. Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A. Eur J Biochem 2001; 268: 4269-4277.
73. Karlström A, Nygren PA. Dual labeling of a binding protein allows for specific fluorescence detection of native protein. Anal Biochem 2001; 295: 22-30.
74. Rönnmark J, Hansson M, Nguyen T, et al. Construction and characterization of affibody-Fc chimeras produced in Escherichia coli. J Immunol Methods 2002; 261: 199-211.
75. Sandström K, Xu Z, Forsberg G, Nygren PA. Inhibition of the CD28-CD80 co-stimulation signal by a CD28-binding affibody ligand developed by combinatorial protein engineering. Protein Eng 2003; 16: 691-697.
76. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
77. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994; 1198: 165-184.
78. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 26: 60-70.
79. Lee, W.M., Walton, S.M.: WO01015730 (2001).
80. Nahta R, Esteva FJ. Traastuzumab: Triumphs and tribulations. Oncogene 2007; 26: 3637-3643
81. Wikman M, Steffen AC, Gunneriusson E, et al. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng Des Sel 2004; 17: 455-462.
82. Carlsson, J., Ståhl, S., Eriksson, T., Gunneriusson, E., Nilsson, F.: WO2005003156 (2005).
83. Orlova A, Magnusson M, Eriksson TL, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006; 66: 4339-4348.
84. Orlova A, Feldwisch J, Abrahmsén L, Tolmachev V. Update: Affibody molecules for molecular imaging and therapy for cancer. Cancer Biother Radiopharm 2007; 22: 573-584.
85. Nakamura Y, Shibasaki S, Ueda M, Tanaka A, Fukuda H, Kondo A. Development of novel whole-cell immunoadsorbents by yeast surface display of the IgG-binding domain. Appl Microbiol Biotechnol 2001; 57: 500-505.
86. Shibasaki S, Kawabata A, Ishii J, et al. Construction of a novel synergistic system for production and recovery of secreted recombinant proteins by the cell surface engineering. Appl Microbiol Biotechnol 2007; 75: 821-828.
87. Fukuda N, Ishii J, Shibasaki S, Ueda M, Fukuda H, Kondo A. High-efficiency recovery of target cells using improved yeast display system for detection of protein-protein interactions. Appl Microbiol Biotechnol 2007; 76: 151-158.
88. Miyashita H, Karaki Y, Kikuchi M, Fujii I. Prodrug activation via catalytic antibodies. Proc Natl Acad Sci USA 1993; 90: 5337-5340.
89. Lin Y, Shiraga S, Tsumuraya T, et al. Comparison of two forms of catalytic antibody displayed on yeast-cell surface. J Mol Catl B Enzym 2004; 28: 241-246.
90. Lin Y, Shiraga S, Tsumuraya T, et al. Isolation of novel catalytic antibody clones from combinatorial library displayed on yeast-cell surface. J Mol Catl B Enzym 2004; 28: 247-251.
91. Tang YQ, Ueda M, Lin Y, et al. Construction of cell surface-engineered yeasts displaying antigen to detect antibodies by immunofluorescence and yeast-ELISA. Appl Microbiol Biotechnol 2008; 79: 1019-1026.
92. Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD. Isolating and engineering human antibodies using yeast surface display. Nat Protoc 2006; 1: 755-768.
93. Lippow SM, Wittrup KD, Tidor B. Computational design of antibody-affinity improvement beyond in vivo maturation. Nat Biotechnol 2007; 25: 1171-1176.
94. Szent-Gyorgyi C, Schmidt BF, Creeger Y, et al. Fluorogen-activating single-chain antibodies for imaging cell surface proteins. Nat Biotechnol 2008; 26: 235-240.
95. Siegel, R.W., Tyner, J.D., Nakagawa, T.Y.: WO2008054517 (2008).
96. Shusta, E.V., Wang, X.X., Cho, Y.P.: WO2007143711(2007).
97. Fukuda T, Shiraga S, Kato M, Suye S, Ueda M. Construction of a cultivation system of a yeast single cell in a cell chip microchamber. Biotechnol Prog 2006; 22: 944-948.
98. Ueda M, Kondo A. Combinatorial bioengineering-Development of molecular evolution. J Mol Catl B Enzym 2004; 28: 137.